Dulaglutide, a GLP-1 receptor agonist, for the treatment of type 2 diabetes

References

• American Diabetes Association. Standards of medical care in diabetes—2015. Diabetes Care. 2015;38(Suppl 1):S1–S93.
   PubMed Web of Science ®Google Scholar
• Garber AJ, Abrahamson MJ, Barzilay JI, et al. AACE comprehensive diabetes management algorithm. Endocr Pract. 2013;19:327–336.
   PubMed Web of Science ®Google Scholar
• Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach. Update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2015;38(1):140–149.
   PubMed Web of Science ®Google Scholar
• Drucker DJ, Nauck MA. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet. 2006;368:1696–1705.
   PubMed Web of Science ®Google Scholar
• Tanzeum [package insert]. Wilmington (DE): GlaxoSmithKline; 2015.
   Google Scholar
• Trulicity [package insert]. Indianapolis (IN): Eli Lilly and Company; 2015.
   Google Scholar
• Byetta [package insert]. Wilmington (DE): AstraZeneca; 2015.
   Google Scholar
• Bydureon [package insert]. Wilmington (DE): AstraZeneca; 2014.
   Google Scholar
• Victoza [package insert]. Plainsboro (NJ): Novo Nordisk, Inc; 2015.
   Google Scholar
• FDA approves Trulicity to treat type 2 diabetes [news release] [Internet]. Silver Spring (MD): US Food and Drug Administration (FDA); 2014 September 18. [cited 2015 May 11]. Available from: http://www.fda.gov/newsevents/newsroom/pressannouncements/ucm415180.htm.
   Google Scholar
• Glaesner W, Vick AM, Millican R, et al. Engineering and characterization of the long-acting glucagon-like peptide-1 analogue LY2189265, a Fc fusion protein. Diabetes Metab Res Rev. 2010;26:287–296.
   PubMed Web of Science ®Google Scholar
• Umpierrez GE, Blevins T, Rosenstock J, et al. The effects of LY2189265, a long-acting glucagon-like peptide-1 analogue, in a randomized, placebo-controlled double-blind study of overweight/obese patients with type 2 diabetes: the EGO study. Diabetes Obes Metab. 2011;13:418–425.
   PubMed Web of Science ®Google Scholar
• Barrington P, Chien JY, Showalter HD, et al. A 5-week study of the pharmacokinetics and pharmacodynamics of LY2189265, a novel, long-acting glucagon-like peptide-1 analogue, in patients with type 2 diabetes. Diabetes Obes Metab. 2011;13:426–433.
   PubMed Web of Science ®Google Scholar
• Barrington P, Chien JY, Tibaldi F, et al. LY2189265, a long-acting glucagon-like peptide-1 analogue, showed a dose-dependent effect on insulin secretion in healthy subjects. Diabetes Obes Metab. 2011;13:434–438.
   PubMed Web of Science ®Google Scholar
• Loghin C, De La Pena A, Cui X, et al. Pharmacokinetics of once daily dulaglutide in special populations. Diabetologia. 2014;57(suppl 1):A880.23.
   Google Scholar
• Wysham C, Blevins T, Arakaki R, et al. Efficacy and safety of dulaglutide added onto pioglitazone and metformin versus exenatide in type 2 diabetes in a randomized controlled trial (AWARD-1). Diabetes Care. 2014;37:2159–2167.
   PubMed Web of Science ®Google Scholar
• Giorgino F, Benroubi M, Sun JH, et al. Efficacy and safety of once-weekly dulaglutide versus insulin glargine in patients with type 2 diabetes on metformin and glimepridie (AWARD-2). Diabetes Care. 2015;Jun 19. [Epub ahead of print].
   PubMedGoogle Scholar
• Umpierrez G, Tofe Povedano S, Perez Manghi F, et al. Efficacy and safety of dulaglutide monotherapy versus metformin in type 2 diabetes in a randomized controlled trial (AWARD-3). Diabetes Care. 2014;37:2168–2176.
   PubMed Web of Science ®Google Scholar
• Blonde L, Jendle J, Gross J, et al. Once-weekly dulaglutide versus bedtime insulin glargine both in combination with prandial insulin lispro, in patients with type 2 diabetes (AWARD-4): a randomized, open-label, phase 3, non-inferiority study. Lancet. 2015;385:2057–2066.
   PubMed Web of Science ®Google Scholar
• Nauck M, Weinstock RS, Umpierrez GE, et al. Efficacy and safety of dulaglutide versus sitagliptin after 52 weeks in type 2 diabetes in a randomized controlled trial (AWARD-5). Diabetes Care. 2014;37:2149–2158.
   PubMed Web of Science ®Google Scholar
• Dungan KM, Povedano ST, Forst T, et al. Once-weekly dulaglutide versus once-daily liraglutide in metformin-treated patients with type 2 diabetes (AWARD-6): a randomised, open-label, phase 3, non-inferiority trial. Lancet. 2014;384:1349–1357.
   PubMed Web of Science ®Google Scholar
• Umpierrez GE, Blevins T, Rosenstock J, et al. The effects of LY2189265, a long-acting glucagon-like peptide-1 analogue, in a randomized, placebo-controlled, double-blind study of overweight/obese patients with type 2 diabetes: the EGO study. Diabetes Obes Metab. 2011;13:418–425.
   PubMed Web of Science ®Google Scholar
• Grunberger G, Chang A, Garcia Soria G, et al. Monotherapy with the once-weekly GLP-1 analogue dulaglutide for 12 weeks in patients with type 2 diabetes: dose-dependent effects on glycaemic control in a randomized, double-blind, placebo-controlled study. Diabet Med. 2012;29:1260–1267.
   PubMed Web of Science ®Google Scholar
• Terauchi Y, Satoi Y, Takeuchi M, et al. Monotherapy with the once weekly GLP-1 receptor agonist dulaglutide for 12 weeks in Japanese patients with type 2 diabetes: dose- dependent effects on glycaemic control in a randomised, double-blind, placebo-controlled study. Endocr J. 2014;published online July 17. DOI:10.1507/endocrj.EJ14-0147.
   Web of Science ®Google Scholar
• Weinstock RS, Guerci B, Umpierrez G, et al. Safety and efficacy of once-weekly dulaglutide versus sitaglipitin after 2 years in metformin-treated patients with type 2 diabetes (AWARD-5): a randomized, phase III study. Diabetes Obes Metab. 2015. DOI:10.1111/dom.12479. [ Epub ahead of print].
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US); 2015. Identifier NCT01394952. Researching Cardiovascular Events with a Weekly Incretin in Diabetes. [cited 2015 Oct 4]. Available from: https://clinicaltrials.gov/ct2/show/NCT01394952?term=REWIND&rank=1.
   Google Scholar
• Ferdinand KC, White WB, Calhoun DA, et al. Effects of the once-weekly glucagone-like peptide-1 receptor agonist dulaglutide on ambulatory blood pressure and heart rate in patients with type 2 diabetes mellitus. Hypertension. 2014;64(4):731–737. DOI:10.1161/HYPEERTENSIONAHA.114.03062. Epub 2014 Jun 30.
   PubMed Web of Science ®Google Scholar
• Kalra S, Gupta Y. DOT (directly observed therapy) in diabetes: current though, future reality. Aust J Rural Health. 2014 Aug;22(4):206. DOI:10.111/ajr.12123.
   Google Scholar